We are delighted to announce that Lumosa's LT3001 (odatroltide) has been shortlisted for the "Clinical Advance of the Year Award" at this year's Pharma Intelligence Scrip Awards. This Award seeks to recognize success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare. Other finalists include Boehringer Ingelheim and Eli Lilly's Jardiance, Daiichi Sankyo and AstraZeneca's Enhertu, Intellia Therapeutics' NTLA-2001, Janssen's Teclistamab, and Servier's Tibsovo.

Oodatroltide addresses the needs of more than 70% of acute ischemic stroke (AIS) patients who are either ineligible to receive proper therapy or are dissatisfied with the treatment outcome. The drug improves stroke treatment rates while expanding treatment coverage, providing neuroprotection, and reducing irreversible damage to the brain tissues. 

https://pharmaintelligence.informa.com/ScripAwards2022